Viking Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Viking Therapeutics, Inc. on May 30, 2018, covering events occurring on May 24 and May 25, 2018. The Company is a Delaware corporation headquartered in San Diego, California, and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, or debt metrics. The only financial obligation disclosed is a new office lease with the following terms:
- Monthly Base Rent: $26,808.75
- Lease Term: November 1, 2018, to January 31, 2022
- Annual Rent Increase: 3.0%
- Space: Approximately 7,149 rentable square feet
- Additional Costs: Electricity, utilities, and certain repair/maintenance obligations
Material Changes
The filing reports two primary material events:
- Office Lease Agreement: The Company entered into a definitive lease with Kilroy Realty, L.P., for its corporate headquarters. The agreement includes a three-year extension option at prevailing market rates.
- Annual Meeting Results: Stockholders voted on director elections and auditor ratification. As of the record date (April 2, 2018), 50,933,195 shares of common stock were issued and outstanding.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks beyond standard lease default provisions. The Company noted that the full text of the lease will be filed as an exhibit to its Form 10-Q for the quarter ending June 30, 2018.
Key Facts for Investor Verification
- Director Election Results: Brian Lian, Ph.D., and Lawson Macartney, DVM, Ph.D., were elected as Class III directors. Significant broker non-votes (approx. 19.9 million shares) were recorded for both nominees.
- Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm with 41,130,032 votes for and 312,611 votes against.
- Lease Commitment: Verify the total cost of the new lease obligation, including the 3.0% annual escalator and potential extension terms, against the Company's cash runway.
- Share Count: Confirm the current number of outstanding shares, as the filing cites 50,933,195 shares as of April 2, 2018.